Influvac Tri

Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26) and Influenza A/Vic, the active ingredients in Influvac Tri, are trivalent influenza vaccines presented as a solution for injection for intramuscular or subcutaneous use. They are intended to induce immunity against seasonal influenza A (including H1N1, H3N2) and influenza B viruses in adults and children.

GNH USA supplies Influvac Tri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality and regulatory compliance.

Influvac Tri is indicated for the prevention of influenza caused by influenza A and B viruses. - Influenza A (H1N1, H3N2): reduces risk of infection and severe disease. - Influenza B (Victoria lineage): provides protection against circulating B strains. - Seasonal influenza outbreaks: offers prophylactic immunity for the flu season.

Influvac Tri may be associated with local and systemic reactions following injection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade temperature rise. - Headache: mild headache within 24 hours. - Myalgia: muscle aches lasting up to two days. - Fatigue: general tiredness after vaccination.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurologic disorder with muscle weakness. - Seizures: infrequent convulsive events post‑vaccination. - High fever: temperature > 39 °C persisting beyond 48 hours. - Severe allergic reaction: urticaria, angioedema, or respiratory distress. - Neurologic events: encephalitis or meningitis symptoms.

Before administering Influvac Tri, consider the following precautions to ensure safe use. - Allergy to egg proteins: avoid vaccination in individuals with severe egg allergy. - History of severe vaccine reaction: contraindicated in persons with prior anaphylaxis to influenza vaccines. - Acute illness: postpone vaccination until recovery from moderate or severe febrile illness. - Immunocompromised patients: vaccine may elicit reduced immune response; assess benefit‑risk. - Pregnancy and breastfeeding: discuss with healthcare provider; vaccine generally considered safe but use based on clinical judgment. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Influvac Tri can interact with certain medical products; observe the following guidance.

Major Interactions (Avoid): - Live attenuated vaccines: do not administer concurrently with live vaccines such as nasal flu spray. - Immunoglobulin or blood products: avoid within 3 months of vaccination as they may neutralize the antigen. - High‑dose corticosteroids: avoid within 2 weeks before or after vaccination due to suppressed immune response.

Moderate Interactions (Monitor Closely): - Antiviral agents (e.g., oseltamivir): may reduce vaccine‑induced antibody response; monitor efficacy. - Immunosuppressive therapy: may diminish immunogenicity; assess protective antibody levels. - Allergic conditions: monitor for enhanced local or systemic reactions in patients with severe atopy.